Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride and Gut Microbiome in Schizophrenia Negative Symptoms
NCT04533724Phase 1Unknown
- Sponsor
- Shanghai Mental Health Center
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of amisulpride in schizophrenia (2 arms), sponsored by Shanghai Mental Health Center. Primary endpoint: The change of intestinal microbial flora at 12 weeks. Status: unknown.
02
Drugs
amisulpride
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04533724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04533724.